文献速递肿瘤 PET/CT

18F-FSPG PET/CT在头颈癌、结直肠癌或非霍奇金淋巴瘤患者的初步评估

Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma.
PubMed 文献 · EJNMMI Res · 2020-08-28

这项研究纳入15例头颈癌、结直肠癌或非霍奇金淋巴瘤患者,比较18F-FSPG与18F-FDG PET/CT的肿瘤摄取。18F-FSPG在多数患者中显示肿瘤摄取,且肿瘤/本底比值高于18F-FDG。研究提示18F-FSPG在三种癌症中具有应用前景,但需更大样本进一步验证。

要点

  • 18F-FSPG在头颈癌、结直肠癌和非霍奇金淋巴瘤中显示肿瘤摄取。
  • 18F-FSPG的肿瘤/本底SUV比值高于18F-FDG。
  • 18F-FSPG与18F-FDG图像多数一致,但存在个体内和个体间摄取差异。

核心结论

  • 18F-FSPG PET/CT在三种癌症中显示有前景的结果,肿瘤/本底比值高于18F-FDG。

研究设计与样本

  • 前瞻性招募15例受试者,头颈癌、结直肠癌和非霍奇金淋巴瘤各5例,平均年龄66.2岁(范围44-87岁)。
  • 每例静脉注射301.4 ± 28.1 MBq(8.1 ± 0.8 mCi)的18F-FSPG,注射后0-2小时内进行3次PET/CT扫描。
  • 所有受试者在18F-FSPG PET扫描前1个月内均接受过阳性的18F-FDG PET/CT扫描,并进行半定量和视觉比较。

主要发现

  • 18F-FSPG在除1例头颈癌患者外的所有头颈癌患者中显示强烈摄取。
  • 18F-FSPG在全部结直肠癌患者中显示肿瘤摄取,但在非霍奇金淋巴瘤患者中摄取可变。
  • 18F-FDG的绝对SUV值等于或高于18F-FSPG,但18F-FSPG的肿瘤/本底SUV比值高于18F-FDG。
  • 18F-FSPG与18F-FDG PET/CT图像之间观察到多数一致的显示,但存在个体内和个体间摄取差异。

临床怎么用

  • 18F-FSPG PET/CT可作为肿瘤显像的潜在工具,尤其关注其较高的肿瘤/本底比值。
  • 对头颈癌患者,18F-FSPG因周围脑本底低可能有助于肿瘤勾画。
  • 目前尚需更大样本研究验证18F-FSPG在不同原发、复发或转移性肿瘤中的效用。

局限性

  • 样本量小(15例),每种癌症仅5例。
  • 研究为初步评估,需更大样本和更广泛肿瘤类型进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: (4S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid ([18F]FSPG) measures system xC- transporter activity and shows promise for oncologic imaging. We present data on tumor uptake of this radiopharmaceutical in human subjects with head and neck cancer (HNC), colorectal cancer (CRC), and non-Hodgkin lymphoma (NHL). METHODS: A total of 15 subjects with HNC (n = 5), CRC (n = 5), or NHL (n = 5) were recruited (mean age 66.2 years, range 44-87 years). 301.4 ± 28.1 MBq (8.1 ± 0.8 mCi) of [18F]FSPG was given intravenously to each subject, and 3 PET/CT scans were obtained 0-2 h post-injection. All subjects also had a positive [18F]FDG PET/CT scan within 1 month prior to the [18F]FSPG PET scan. Semi-quantitative and visual comparisons of the [18F]FSPG and [18F]FDG scans were performed. RESULTS: [18F]FSPG showed strong uptake in all but one HNC subject. The lack of surrounding brain uptake facilitated tumor delineation in the HNC patients. [18F]FSPG also showed tumor uptake in all CRC subjects, but variable uptake in the NHL subjects. While the absolute [18F]FDG SUV values were comparable or higher than [18F]FSPG, the tumor-to-background SUV ratios were greater with [18F]FSPG than [18F]FDG. CONCLUSIONS: [18F]FSPG PET/CT showed promising results across 15 subjects with 3 different cancer types. Concordant visualization was mostly observed between [18F]FSPG and [18F]FDG PET/CT images, with some inter- and intra-individual uptake variability potentially reflecting differences in tumor biology. The tumor-to-background ratios were greater with [18F]FSPG than [18F]FDG in the cancer types evaluated. Future studies based on larger numbers of subjects and those with a wider array of primary and recurrent or metastatic tumors are planned to further evaluate the utility of this novel tracer.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Park SY, Mosci C, Kumar M, et al. Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma. EJNMMI Res. 2020. PMID: 32857284. doi:10.1186/s13550-020-00678-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。